Vaccines

A regulatory panel has given the vaccine approval leaving only the official EUA approval before distribution.

The organizations also thanks healthcare professionals for their work throughout the pandemic.

A survey has found an increase in the share of the general public willing to receive a COVID-19 vaccine.

The organization supports recommendations for the Pfizer BioNTech vaccine.

The vaccine is expected to be authorized for emergency use later this week.

The authorization came late Friday night.

The Vaccines and Related Biological Products Advisory Committee approved the vaccine, BNT162b2, paving the way to emergency use authorization.

The report came out as the U.K. has started vaccinating patients.

As National Influenza Vaccination Week approaches, it’s time for all adults to get a flu shot.

The UK leapfrogged the rest of the western world in accepting the candidate which is shown to be about 95 percent effective against COVID-19.

The organization is recommending a framework to ensure ethical allocations of much-needed vaccines during the pandemic.

The candidate showed 94.1 percent efficacy against COVID-19 and 100 percent against severe COVID-19.

The company tested two different dosing regimens with one shown to be more effective.

The candidate BNT162b2 was shown to be 95 percent effective against COVID-19.

BNT162b2 showed 95 percent efficacy against COVID-19.

The latest vaccine candidate showed about 95 percent efficacy in a Phase 3 trial.

These new codes ensure physicians get paid for keeping their patients safe from COVID-19.

The candidate was shown to be more than 90 percent effective in preventing COVID-19 infection.

With infections on the rise at the start of flu season, the need for measures to limit transmission is as strong as ever.

The interim final rule with comment period would make the vaccine free to patients on Medicare and on most private health plans.

Concerns over efficacy and politics clouds hope for a vaccine to end the COVID-19 pandemic.

In an open letter, CEO Albert Bouria sought to give clarity to the drug’s development timeline.

The trial had been halted due to a side-effect in an English patient.

The pledge seeks to assuage fears that the Trump administration will rush a vaccine into production for political purposes.

In a letter, the agency pushes states to fast-track permitting and licensing for possible distribution sites.